{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:45:58Z","timestamp":1767134758136,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd002064.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":20,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002064.pub3","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T19:26:43Z","timestamp":1352402803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis\/motor neuron disease"],"prefix":"10.1002","volume":"2012","author":[{"given":"Michel","family":"Beauverd","sequence":"first","affiliation":[{"name":"Service de Soins Palliatifs, Centre Hospitalier Universitaire Vaudois (CHUV); Avenue Pierre Decker 5 Lausanne Vaud Switzerland 1011"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J D","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Royal Preston Hospital; Preston MND Care & Research Centre; Preston UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John HJ","family":"Wokke","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht; Department of Neurology; Rudolf Magnus Institute of Neuroscience Utrecht Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Domenico","family":"Borasio","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois (CHUV); Service de Soins Palliatifs; University of Lausanne Lausanne Switzerland CH-1011"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD002064.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1212\/WNL.51.2.583","article-title":"A placebo controlled trial of insulin-like nerve growth factor-1 in amyotrophic lateral sclerosis","volume":"51","author":"Borasio","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD002064.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"issue":"22","key":"10.1002\/14651858.CD002064.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-I is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002064.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1179\/016164105X39860","article-title":"Beneficial effects of intrathecal IGF-I administration in patients with amyotrophic lateral sclerosis","volume":"27","author":"Nagano","year":"2005","journal-title":"Neurological Research"},{"issue":"1","key":"10.1002\/14651858.CD002064.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01277964","article-title":"Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis","volume":"97","author":"Adem","year":"1994","journal-title":"Journal of Neural Transmission. General Section"},{"issue":"3","key":"10.1002\/14651858.CD002064.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.410220308","article-title":"A rating scale for amyotrophic lateral sclerosis: description and preliminary experience","volume":"22","author":"Appel","year":"1987","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD002064.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/WNL.33.7.911","article-title":"Geographic distribution of motor neuron disease and correlation with possible etiologic factors","volume":"33","author":"Bharucha","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD002064.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1083\/jcb.110.4.1307","article-title":"Nerve sprouting in innervated adult skeletal muscle induced by elevated levels of insulin-like nerve growth factors","volume":"110","author":"Caroni","year":"1990","journal-title":"Journal of Cell Biology"},{"key":"10.1002\/14651858.CD002064.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1749-6632.1993.tb26219.x","article-title":"Activity-sensitive signals by muscle-derived IGFs in the developing and regenerating neuromuscular system","volume":"692","author":"Caroni","year":"1993","journal-title":"Annals of the New York Academy of Science"},{"issue":"1-2","key":"10.1002\/14651858.CD002064.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0169-328X(96)00081-2","article-title":"Distribution and levels of insulin like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients","volume":"41","author":"Dore","year":"1996","journal-title":"Brain Research. Molecular Brain Research"},{"key":"10.1002\/14651858.CD002064.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"issue":"Suppl","key":"10.1002\/14651858.CD002064.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0022-510X(95)00081-C","article-title":"Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease","volume":"129","author":"Hantai","year":"1995","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD002064.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/brain\/118.3.707","article-title":"Natural history of amyotrophic lateral sclerosis in a database population - validation of a scoring system and a model for survival prediction","volume":"118","author":"Haverkamp","year":"1995","journal-title":"Brain"},{"key":"10.1002\/14651858.CD002064.pub3-BIB0014|cit14","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002064.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-I prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD002064.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/exnr.1993.1177","article-title":"Insulin-like growth factor-1: potential for treatment of motor neuronal disorder","volume":"124","author":"Lewis","year":"1993","journal-title":"Experimental Neurology"},{"issue":"5","key":"10.1002\/14651858.CD002064.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD002064.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-510X(99)00209-9","article-title":"Consensus guidelines for the design and implementation of clinical trials in ALS","volume":"169","author":"Miller","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD002064.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/jnnp.65.6.842","article-title":"Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and South Cumbria","volume":"65","author":"Mitchell","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD002064.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/neu.480241203","article-title":"Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival","volume":"24","author":"Neff","year":"1993","journal-title":"Journal of Neurobiology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002064.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T20:04:10Z","timestamp":1742760250000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002064.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002064.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}